arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Pulmonx Corp

LUNG
$2.58 ▼ -0.24 (-8.51%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
33 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Pulmonx Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $111.4M
Dividend Yield —
Revenue Growth 6.2% ↗
Op. Margin -32.8% ↗
ROIC -10.6% ↗
FCF / Share $-0.07 ↗
Trailing P/E —
Price / Book 3.3x
FCF Yield —
Debt / Equity 1.11
info Valuation on last close. End-of-day price, Nov 5, 2026.

33-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$22.84M
↑ +6.2% —
Net Income Profit after all expenses
$-13.65M
↑ +5.5% —
Operating Margin Operating profit as % of sales
-32.8%
↑ +17.6% 4th
FCF / Share Free cash flow per share
$-0.07
↑ +39.8% —
Long-Term Debt Long-term obligations
$37.81M
↑ +0.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
5
Returns ↓
9
Financial Health ↑
33
Cash Quality ↓
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 33 quarters